Host vs Graft Reaction, Liver Transplantation, Transplantation Immunology
Conditions
Keywords
Immunosuppressant, Graft loss, Combination drug therapy, Randomized controlled trial, Open level method
Brief summary
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF and steroid withdrawal in de novo Liver transplant recipients
Interventions
Sponsors
Astellas Pharma Taiwan, Inc.
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures * Patient is a primary liver transplant recipient * Patient must receive first dose of XL or Prograf (or IV tacrolimus for subjects unable to tolerate oral study drug) within 48 hours of transplantation * Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to transplant
Exclusion criteria
* Patient has previously received or is receiving an organ transplant other than a liver * Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV) * Patient has received a liver transplant from a non-heart beating donor * Patient has received an ABO incompatible donor liver * Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria 21 and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully * Patient has fulminant hepatic failure, unless hemodynamically stable * Patient has an uncontrolled concomitant infection, a systemic infection requiring treatment (except viral hepatitis), or any other unstable medical condition that could interfere with the study objectives * Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus * Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant * Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or corticosteroids * Patient is pregnant or lactating * Patient is unlikely to comply with the visits scheduled in the protocol, including the protocol biopsies * Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of biopsy confirmed acute rejection (local assessment of biopsies performed due to hepatic dysfunction) during the 6 months post-transplant. | 6 month |
Secondary
| Measure | Time frame |
|---|---|
| Patient and graft survival rates during the 6 and 12 months post-transplant | 6 and 12 month |
| Incidence of biopsy confirmed acute rejection (local assessment of biopsies performed due to hepatic dysfunction) during the 12 months post-transplant | 12 month |
| Incidence of anti-lymphocyte antibody therapy for treatment of rejection during the 6 and 12 months post-transplant | 6 and 12 month |
Countries
Taiwan
Outcome results
None listed